文献速递胸部肿瘤

HER2介导KRASG12C抑制剂sotorasib的临床耐药,联合靶向SHP2可克服

HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.
PubMed 文献 · Eur J Cancer · 2021-10-26

该研究通过一例接受sotorasib治疗后进展的肺癌患者活检,发现HER2拷贝数增加与KRASG12C突变保留,提示HER2扩增是耐药机制;体外和体内模型显示MAPK通路持续激活,联合抑制KRASG12C和SHP2可协同克服HER2介导的耐药。

要点

  • HER2拷贝数增加是KRASG12C抑制剂sotorasib的临床耐药机制。
  • HER2扩增的KRASG12C肺癌模型中MAPK通路在用药后仍持续激活。
  • 联合抑制KRASG12C和SHP2可协同克服HER2介导的耐药。

核心结论

  • HER2拷贝数增加是KRASG12C药理学抑制的临床相关耐药机制,可通过联合靶向SHP2克服。

研究设计与样本

  • 研究分析了一例接受KRASG12C抑制剂sotorasib治疗后进展的肺癌患者活检组织,并进行体外和体内机制研究。

主要发现

  • 进展后活检显示HER2拷贝数增加且KRASG12C突变保留。
  • 过表达HER2的KRASG12C肺癌模型中,MAPK通路信号在KRASG12C抑制剂治疗后仍保持活跃。
  • 联合药理学抑制KRASG12C和SHP2在体外和体内协同克服HER2介导的耐药。

临床怎么用

  • 对KRASG12C抑制剂sotorasib治疗后进展的患者,可考虑检测HER2拷贝数增加以明确耐药机制。
  • 针对HER2介导的耐药,联合靶向KRASG12C和SHP2是潜在克服策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Mutant RAS guanosine triphosphate hydrolases (GTPases) are key oncogenic drivers in many cancers. The KRASG12C variant has recently become targetable by a new drug class specifically locking KRASG12C in its inactive guanosine diphosphate (GDP)-bound state. Clinical activity was demonstrated in patients with advanced lung cancers harbouring KRASG12C mutations but was limited by the development of resistance. METHODS: A biopsy from progressing lung cancer of a patient treated with the KRASG12C inhibitor sotorasib was obtained, and the underlying resistance factors were analysed. Mechanistic studies were performed in vitro and in vivo to uncover strategies to overcome resistance to KRASG12C inhibition. RESULTS: We demonstrated acquisition of HER2 copy number gain and KRASG12C mutation retention in the post-progression biopsy. To explore HER2 gain as the relevant resistance mechanism, we generated KRASG12C lung cancer models overexpressing HER2. MAPK pathway signalling remained active despite KRASG12C inhibitor treatment. Combined pharmacological inhibition of KRASG12C and SHP2 synergistically overcame HER2-mediated resistance in vitro and in vivo. CONCLUSIONS: These findings establish HER2 copy number gain as a clinically relevant mechanism of resistance to pharmacological KRASG12C inhibition that can be overcome by co-targeting SHP2.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ho CSL, Tüns AI, Schildhaus HU, et al. HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. Eur J Cancer. 2021. PMID: 34715459. doi:10.1016/j.ejca.2021.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。